Drugs / JNJ-61818549
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02218073 | Oct → Dec 2014 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02231489 Background | Sep → Nov 2014 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-61818549 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02218073 ↗ |
| Route | Intravenous | “JNJ-61818549 as intravenous injection” NCT02218073 ↗ |